MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28

Rhea-AI Filing Summary

MAIA Biotechnology CEO Vitoc Vlad received a grant of 800,000 stock options as equity compensation. The options give him the right to buy 800,000 shares of common stock at an exercise price of $1.28 per share and expire on April 10, 2036.

The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, Vlad holds 800,000 options directly, and the filing shows no open-market stock purchases or sales.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vitoc Vlad

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	800,000	$0.00	--

Holdings After Transaction: Stock Options — 800,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 800,000 options Exercise price: $1.28 per share Underlying shares: 800,000 shares +4 more

7 metrics

Option grant size 800,000 options Stock options granted on April 10, 2026

Exercise price $1.28 per share Exercise price for the 800,000 options

Underlying shares 800,000 shares Common stock underlying the options

Expiration date April 10, 2036 Option term end date

Post-grant derivative holdings 800,000 options Total options held following the transaction

Initial vesting cliff 25% after 1 year First anniversary of April 10, 2026 grant date

Remaining vesting period 36 months monthly Residual vesting after initial 25% cliff

Key Terms

Stock Options, 2021 Equity Incentive Plan, vesting schedule, underlying security, +1 more

5 terms

Stock Options financial

"The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

vesting schedule financial

"vest on a 4-year vesting schedule, with 25% of the options to vest"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

underlying security financial

"underlying_security_title": "Common Stock""

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitoc Vlad

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.28	04/10/2026		A		800,000		04/10/2027(1)	04/10/2036	Common Stock	800,000	$0	800,000	D

Explanation of Responses:

1. The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

	/s/ Vlad Vitoc	04/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MAIA (MAIA) CEO Vitoc Vlad report in this Form 4?

Vitoc Vlad reported receiving a grant of 800,000 stock options as compensation. These options allow him to buy MAIA Biotechnology common shares at a fixed $1.28 exercise price, with vesting tied to a four-year service schedule under the company’s 2021 Equity Incentive Plan.

How many MAIA (MAIA) stock options were granted to the CEO and at what price?

Vitoc Vlad was granted 800,000 stock options. Each option permits the purchase of one share of MAIA Biotechnology common stock at an exercise price of $1.28 per share, providing potential future ownership if the options vest and are exercised according to plan terms.

What is the vesting schedule for Vitoc Vlad’s MAIA (MAIA) stock options?

The options vest over four years. Twenty-five percent of the 800,000 options vest on the first anniversary of the April 10, 2026 grant date, with the remaining options vesting ratably in equal monthly installments over the following 36 months, subject to continued service.

When do the MAIA (MAIA) stock options granted to the CEO expire?

The granted stock options expire on April 10, 2036. If not exercised by that date, the right to purchase MAIA Biotechnology common shares at the $1.28 exercise price lapses, consistent with typical long-term equity incentive award structures.

Did the MAIA (MAIA) CEO buy or sell common stock in the market in this filing?

No open-market purchases or sales of common stock are shown. The Form 4 reports only a compensation-related acquisition of 800,000 stock options, not a market trade, with all ownership classified as direct and tied to the equity incentive grant.